Ascentage Pharma Becomes a Constituent of Three Major Indexes Including Hang Seng Composite Index

SUZHOU, China, and ROCKVILLE, MD., Aug. 16, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the company...

from PR Newswire: https://ift.tt/3kQhD3Q